An experimental drug from Celldex Therapeutics induced complete symptom relief in half of patients with chronic and severe hives — study results that are still preliminary but suggest a new way to tamp down immune reactions that can trigger the debilitating skin condition.
The new data also validate Celldex’s strategic decision, taken two years ago, to pivot to treatments for autoimmune disease, following multiple setbacks with cancer therapies.
In the early-stage study, four of eight patients treated with infusions of the Celldex drug called barzolvolimab, spaced one month apart, achieved a complete response, meaning total elimination of painful welts, skin inflammation, and itching.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
